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Background: Population aging is a common demographic pattern in developed countries, and 
aging increases the risk of cancer. The disproportionately high cancer burden, as a consequence, 
is especially pronounced in Central and Eastern European countries, including Hungary. 
Methods: We summarized current and projected future cancer incidences and mortalities 
utilizing data from the last two decades. Predictions are based on cancer incidence and mor-
tality collected between 1996 and 2015 in Hungary. In addition to the crude rates, data were 
age standardized to the European standard population (ESP) of 2013, ESP of 1976, and local 
census of 2011.
Results: The lifetime probability of developing cancer and cancer-related mortality has already 
reached 56.9% and 27.6% in men, respectively, and 51.9% and 21.7% in women. Between 2016 
and 2030, the total population is expected to shrink by 6%, while the number of 60-year olds and 
above will grow by 18%. This will lead to a 35% increase in cancer incidence and 30% increase 
in cancer death among 65–85-year olds. Joinpoint regression identified the period 2007–2015 
as starting point for this coming increase in new cases. In women, lung and breast cancer will 
increase yearly by 1.9% and 1.7%, respectively, between 2016 and 2030, while in men, the 
prostate and colorectal cancer rates will increase yearly by 3.6% and 2.1%.
Conclusion: In the aging population of Hungary, cancer incidence will increase consider-
ably over previous projections. Although a large portion of the most rapidly rising cancers are 
avoidable by implementing public health programs, a substantial portion remains inevitably 
incurable.
Keywords: cancer, biostatistics, aging, lung cancer, colon cancer, breast cancer, prostate cancer
Introduction
Projecting in advance the incidence and mortality of diseases is crucial to identify 
major focal points for research and for preventive health programs, and it helps to 
limit shortfalls in diagnostic procedures and interventions. Resources need to be 
prioritized for funding and for improvements in quality of life. These considerations 
are especially important for countries with high cancer rates and with rapid, ongoing 
population transformations.
Population aging is a common demographic pattern across most developed coun-
tries. With an average fertility of 1.6 children per woman and a life expectancy of 77 
years, Europe has the highest proportion of population aged 60 years or over (24%). The 
total number of inhabitants is projected to be below the 2015 level in 2050.1 Inhabited 
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by only 10% of the total world population, Europe is over-
whelmed by 24.4% of the global cancer incidence and 21.5% 
of cancer-related mortality.2 The majority of Central, Eastern, 
and Southern Europe, with fertility rates at or below 1.5, is 
experiencing an even more accelerated demographic change.
The epidemiological cancer burden of Hungary is among 
the highest in Europe,3 including the highest cancer-related 
overall mortality in men (estimated age-standardized rates 
[ASRs]: 306.3 in Hungary vs. 222.5 in Europe) and the third 
highest mortality among women (163.6 vs. 128.8 in Europe). 
Among 40 European countries, the incidence of lung and 
bronchus cancer (LC), colon and rectum cancer (CRC), and 
oral cavity-pharynx cancers is highest in Hungary among 
both males and females.1,3 Neighboring countries, such as 
the Czech Republic, Slovenia, Slovakia, Croatia, and Serbia, 
experience cancer incidences comparable to Hungary.3,4 At 
the same time, Hungary has a traditionally high autopsy rate 
of 37% compared to only 15% for other European Union 
(EU) members according to the WHO European Health 
Information Gateway (or to less than 1% in the UK).5 The 
National Cancer Registry covers 100% of the population – 
hospitals are required by law to report cancer-related data to 
the National Cancer Registry quarterly [24/1999. (VII. 6.) 
EüM] (https://uj.jogtar.hu/#doc/db/1/id/99900024.EUM/), 
followed by data verification performed by the Registry, 
which usually takes up to 3 years. The combination of out-
standingly reliable medical data in an aging country with high 
cancer burden makes Hungary a good model to predict trends 
in cancer epidemiology for countries with similar predica-
ments. Our model offers extrapolations, especially for the 
Central and Eastern European regions, where demography 
and cancer burden are similar across countries.3
Comparing cancer incidence and mortality patterns across 
countries or over time within a population requires standard-
ization. The ASR is a weighted mean of age specific rates. The 
weights are taken from a standard population (World Stan-
dard Population or European Standard Population [ESP]),6 
frequently expressed per 100,000 person-years. While ASR 
approximates the population’s risk of being diagnosed with 
cancer, it does not incorporate the effect of demographic 
change on cancer burden and does not provide clear projec-
tions of the local patterns within a given country.
Current fertility rates are projected to shift the age 
distribution further in developed countries. Thus, cancer 
incidence rates are expected to markedly increase. Here, 
our aim is to use epidemiologic data available in Hungary 
to provide straightforward, site-specific predictions for all 
major cancers, serving as a reference for countries struggling 
with similar rapid demographic changes coupled with high 
cancer rates. To assess the impact of changes in the population 
age structure and current risk trends, we utilize data of the 
National Cancer Registry and the Central Statistical Office of 
Hungary to project future cancer incidence and mortality for 
major cancer sites for 2020, 2025, and 2030 based on inci-
dence and mortality data collected between 1996 and 2015. 
Methods
source of data
Population-based incidence data for the period between 2001 
and 2014 were collected by the National Cancer Registry of 
Hungary. Mortality data for the time frame between 1996 
and 2015 were acquired from the Central Statistical Office 
of Hungary. The National Cancer Registry of Hungary was 
established in 2000 to replace former hospital-based data 
collection systems, and it remains in close contact with com-
munity hospitals to ensure the quality of the compiled data. 
Since 2001, the collected incidence data are publicly available. 
All cancer cases are classified according to the International 
Statistical Classification of Diseases and Related Health 
Problems, 10th revision.7
Demographic projections by age group and sex were 
based on data obtained from the Hungarian Demographic 
Research Institute. For mortality calculations and projections, 
data were tabulated into four 5-year periods (1996–2000, 
2001–2005, 2006–2010, and 2011–2015) and three 1-year 
periods (2020, 2025, and 2030). For calculations and projec-
tions of cancer incidence, data were arranged into three 5-year 
periods (2001–2005, 2006–2010, and 2011–2015) and three 
1-year periods (2020, 2025, and 2030). The incidence for 
2011–2015 was incomplete because of the lag in data avail-
ability. The missing values were substituted with the mean of 
the two most recent years with complete data. In this study, 
only anonymized patient data were included and analyzed.
age-standardization of incidence and 
mortality rates
Population metrics of the ESP were updated in 2013,6 based on 
2010–2030 population projections. The ESP is the unweighted 
average of individual populations of EU-27 and European 
Free Trade Association (EFTA) countries in each 5-year age 
band. All incidence and mortality data were age standardized 
to the 2013 ESP and expressed per 100,000 people.6
As a consequence of this step, our main results cannot be 
directly compared with publications using the previous, 1976 
ESP data. To overcome this limitation and enable comparison 
of different metrics, we listed the observed and estimated 
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cancer incidence in Hungary by site and sex as (1) crude 
rates, (2) ASR using the Hungarian population based on the 
2011 Hungarian census, (3) ASR using the 1976 ESP, and 
(4) ASR using the 2013 ESP.
statistical analysis
Cancer incidence and mortality were calculated in the R pro-
gramming environment using the Nordpred package devel-
oped by the Cancer Registry of Norway.8 This is a modified 
age-period-cohort regression model,9 with incidence counts 
assumed to follow a Poisson distribution, based on 5-year 
age groups and 5-year calendar periods. Birth cohorts were 
constructed synthetically by subtracting age from period.10
The formula of the original age-period-cohort model 
is: R
ap 
= exp(A
a 
+ D·p + P
p 
+ C
c
), where R
ap
 is defined as the 
mortality and incidence rate in age group (a) and in calendar 
period (p); D is the common drift parameter, and the D of the 
first, second, and third periods was reduced by 0%, 25%, 50%, 
respectively; A
a
 is the age component of age group (a); P
p
 is 
defined as the nonlinear period component of period (p); and 
C
c
 is the nonlinear cohort component of cohort (c). To obtain 
better predictions, we used the power link function according 
to the recommendations proposed by Møller et al.7 The start-
ing age group of the model was determined by considering 
the number of deaths or number of cases in each cell. If the 
number of cases was less than 10 in the age group, future 
rates were calculated using the average of the last 10 years.
Trends in observed and projected data using segmented 
line regression were calculated with joinpoint regression,11 
with up to four joinpoints allowed between 2001–2030 for 
incidence and 1996–2030 for mortality, following the previ-
ously published method.12 The likelihood of being diagnosed 
with cancer and the probability of cancer death were com-
puted with the DevCan software,13 according to the previous 
descriptions of the statistical model.14,15
Results
Observed cancer cases and deaths, 2006–
2015
In the past 10 years, a total of 712,785 new cancer cases 
were diagnosed in Hungary, 364,004 in men and 348,781 
in women. This number corresponds to approximately 195 
new cancer cases diagnosed per day. In men, LC, CRC, and 
prostate cancers accounted for 45% of all cases. Cancers of 
the oral cavity and pharynx accounted for 8% of all cases in 
men. In women, breast, CRC, and LC accounted for 46% of 
all cases diagnosed, breast cancer alone responsible for 21%.
In the same time period, 331,119 cancer-related deaths 
occurred in Hungary, and 33,781 more males died than 
females. This corresponds to approximately 92 cancer-related 
deaths per a day. In men, LC and CRC were the most lethal 
cancers, accounting for 45% of all cases. Oral cavity and 
pharynx cancers and prostate cancers each accounted for 
7% of all cancer-related deaths. In females, LC, CRC, and 
breast cancers were responsible for 20%, 14%, and 14% of 
all deaths, respectively. The two most lethal cancers, LC and 
CRC, accounted for 40% of all cancer-related deaths in the 
entire population. The observed new cancer cases and deaths 
in 2006–2015 are summarized in Table 1.
Both the lifetime probability of developing cancer and 
cancer-related death rate were higher in men (56.9% and 
27.6%) compared to women (51.9% and 21.7%). However, 
below 50 years of age, cancer risk was higher in females, 
probably due to the high burden of breast cancer, thyroid 
cancer, and cancers of the female reproductive organs. 
Based on the most recent available data, one out of every 10 
women was diagnosed with breast cancer, and one in every 
10 men with LC.
Demographic shift will boost age groups 
with high cancer incidence and mortality
Between 2016 and 2030, the Hungarian population is 
expected to shrink by 6% compared to 2015. The age dis-
tribution is forecasted to be heavily skewed (Figure 1) – the 
number of 60-year olds and above is estimated to grow 
roughly by 18%, while 12% fewer males and 14% fewer 
females will be among those aged less than 60 years. The 
number of those 30–34 years old is expected to be reduced 
by roughly 24% in men and 26% in women.
Cancer primarily affects older individuals. As a conse-
quence, the decreasing proportion of younger generations 
will result in the marked decline of cohorts with low cancer 
burden. Accordingly, among the 65–85-year olds, ~35% 
more patients are projected to be diagnosed with cancer in 
2016–2030 compared to 2001–2015 (844,000 vs. 541,000), 
and ~30% more cancer-related deaths are expected (399,000 
vs. 303,000).
The gradually changing population composition will 
result in discordant trends between crude and ASRs of mor-
tality and the incidence split by sex (Figure 2). In males, 
the ASR of the overall incidence culminated in 2011–2015, 
whereas it continues to gently rise in females. The ASR of 
overall mortality reveals similar directions: a decreasing trend 
in males and a slow but steady increase in females.
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The mean annual percentage increase in 
incidence is over 1.35%
The mean annual percentage change (APC) in crude rates of 
cancer incidence modeled by joinpoint regression predicts 
a 1.35% annual increase between 2001 and 2030 in male 
overall incidence and a 1.68% annual increase between 2013 
and 2030 in female overall incidence (p < 0.05) (Figure 2). 
In males, the LC incidence rates are in a steady decline 
( Figure 3), yet the steep increase in the incidence of other 
major cancer types (e.g., prostate, bladder, kidney, pan-
creas, CRC) explains the overall increase in incidence for 
2001–2014, with similar tendencies expected in the future 
(Table 2A). A numerical example of the age-period-cohort 
model in males illustrates the performed calculations in 
 Supplementary materials. In females, accelerated annual 
growth characterizes many of the less frequent cancer 
types, such as thyroid, liver, bladder, and kidney cancers and 
non-Hodgkin lymphoma, with rates projected to persist for 
2015–2030 (Table 2A).
The annual percent change in crude overall mortality 
based on joinpoint regression analysis from 1996 through 
2030 projects a 0.78% annual increase in the overall mortality 
rate in males between 2015 and 2030 and a 1.47% annual 
increase between 2008 and 2030 for females (p < 0.05) 
(Figure 2). The inflated female trends are partly caused by 
the steep increase in LC-related mortality. In addition, the 
annual increase will be higher in several (e.g., pancreas, 
kidney) cancer-related mortalities for females compared to 
males (Table 2B).
Current and projected cancer incidence 
and mortality trends by site of origin
In males, the incidence of CRC, with its calculated 2.1% 
annual increase, is projected to surpass LC and is predicted 
to be the most common cancer by 2020 (Table 3). The inci-
dence of prostate cancer, with an astounding 3.6% annual 
increase, is expected to achieve the top position alongside 
CRC (Table 3) in males 60 years and up (Table 4A). The inci-
dence of prostate cancer is age dependent, but it is predicted 
to be among the five most common cancers in men as young 
as 40. Oral cavity/pharynx cancer along with kidney cancer 
will be frequent among 40–59-year-old males, as will blad-
der cancer among those over 60 years of age (Table 4A). The 
annual increases in pancreas, bladder, stomach, and kidney 
Table 1 Distribution of cancer incidence (a) and mortality (B). incidence and mortality values represent the period 2006–2015
(A) (B) 
Incidence Mortality
Males Females Males Females
lung and bronchus 19.3% Breast 20.9% lung and bronchus 30.5% lung and bronchus 19.7%
Colorectal 15.0% Colorectal 13.2% Colorectal 15.0% Colorectal 14.2%
Prostate 11.0% lung and bronchus 12.3% Oral cavity and pharynx 6.8% Breast 14.2%
Oral cavity and pharynx 7.5% Corpus uteri 4.0% Prostate 6.6% Pancreas 6.5%
Bladder 5.8% Ovary 3.6% stomach 5.3% stomach 4.9%
stomach 3.8% Pancreas 3.6% Pancreas 5.0% Ovary 4.7%
Kidney 3.4% Melanoma of skin 3.2% Bladder 3.4% leukemia 3.0%
Pancreas 3.3% Cervix uteri 3.1% liver 2.8% gallbladder and biliary tract 2.9%
larynx 2.8% stomach 3.0% Esophagus 2.7% Cervix uteri 2.8%
Melanoma of skin 2.7% Bladder 2.7% larynx 2.6% Brain 2.0%
Brain 2.6% Oral cavity and pharynx 2.7% leukemia 2.6% Oral cavity and pharynx 1.9%
leukemia 2.5% Kidney 2.6% Kidney 2.4% Kidney 1.9%
liver 2.5% non-hodgkin lymphoma 2.5% Brain 1.7% non-hodgkin lymphoma 1.9%
non-hodgkin lymphoma 2.2% Brain 2.5% non-hodgkin lymphoma 1.6% liver 1.8%
Esophagus 1.9% leukemia 2.4% gallbladder and biliary tract 1.2% Bladder 1.8%
soft tissue 1.8% soft tissue 2.0% Melanoma of skin 1.1% Corpus uteri 1.8%
Testis 1.6% gallbladder and biliary tract 1.9% Multiple myeloma 0.7% Melanoma of skin 1.0%
gallbladder and biliary tract 1.2% liver 1.8% Testis 0.3% Multiple myeloma 1.0%
Bones and joints 1.0% Thyroid 1.4% Bones and joints 0.1% Esophagus 0.7%
Thyroid 0.4% Bones and joints 0.9% hodgkin lymphoma 0.1% larynx 0.4%
Other 7.6% Other 9.5% Other 7.6% Bones and joints 0.1%
all sites 100% all sites 100% all sites 100% hodgkin lymphoma 0.1%
   Other 10.8%
   all sites 100%
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cancer-related mortality are projected to continue in the future 
(Table 2B), and by 2030, besides LC and CRC, prostate, 
pancreas, bladder, and stomach cancers are predicted to be 
the most common causes of cancer-related deaths among 
men (Table 3).
Among those aged 20–39 years, the incidences of tes-
ticular cancer and melanoma are forecasted to precede CRC. 
Non-Hodgkin lymphoma and brain cancers will also be on 
the rise (Table 4A). Among the less common tumor types, 
the incidence of thyroid cancer (3.2% annually) is estimated 
to grow with the fastest pace (Table 2A).
LC-related mortality has already climaxed in males 
( Figure 3), yet it remains a top killer among those aged 
40–79 years (Table 4B). Oral cavity and pharynx cancer-
related mortality started a steep, uninterrupted decline in 
2006–2015 (Table 2B), while it remains among the three 
most common death-causing cancers among those aged 
40–59 years (Table 4B).
In females, the incidences of breast cancer, CRC, and 
LC are projected to remain in the top positions until 2030 
(Table 3). However, among those 20–39 years old, the inci-
dences of melanoma, cervix uteri, and thyroid cancers are 
projected to surpass CRC and LC (Table 4A). The incidence 
of breast cancer is predicted to rise predominantly among 
those 40–59 years old. Pancreas cancer, with its estimated 
3% annual increase, is estimated to reach 4% incidence by 
2020, mainly affecting women past 60 years of age (Table 
4A). Among less common cancer types, the increases in 
the incidences of thyroid, soft tissue, and liver cancers 
will be considerable (Table 2A). LC, CRC, breast cancer, 
and pancreas cancer are predicted to remain top causes of 
cancer-related death in females through 2030 (Table 3). The 
Figure 1 Upcoming shift in population age distribution increases the number of new cancer cases.
Note: Population age distribution in female (A) and male (B), cancer incidence rates in female (C) and male (D), and mortality in women (E) and men (F).
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steep increase in mortality already present in 1996–2005 
is expected to continue for bladder, pancreas, and ovarian 
cancers. Ovarian cancer will be among the top five death-
causing cancers among women aged 40–79 years, surpassed 
by stomach cancer-related mortality among those aged 80+ 
years (Table 4B). Mortality and incidence trends are depicted 
as both crude rates and ASRs for each major cancer type in 
Figure 4A for women and Figure 4B for men.
Comparing different reference 
populations
To study cancer rates standardized to different reference 
populations, we compared cancer incidence and mortality by 
site (standardized to the 1976 ESP) with the 2012 estimates of 
overall European cancer incidence and mortality.3 Of the most 
rampant cancers, a 45% higher incidence rate of LC among 
males and 56% among females was observed in Hungary. For 
pancreas cancer, the incidence was 46% and 41% higher in 
males and females, respectively, and for CRC the incidence 
was 41% higher among men and 36% among women. The 
incidence of gallbladder cancer among men and women was 
65% and 58% higher, respectively. The incidence of cancers 
of the oral cavity and pharynx was 63% and 61% higher 
among males and females, respectively, than the estimated 
European average. Mortality from oral cavity/pharynx cancer 
and larynx cancer was 67% and 59% higher, respectively, 
than the European average among men. CRC-related death 
was 52% greater in men and 41% greater in women than the 
European average, and 42% versus 49.5% greater mortality 
was observed among males and females, respectively, as a 
result of LC. We list the observed and estimated cancer inci-
dences in Hungary by site and sex in Table S1 as (1) crude 
rates, (2) ASRs using the Hungarian population based on the 
2011 Hungarian census, (3) ASRs using the 1976 ESP, and 
(4) ASRs using the 2013 ESP. Mortality data with the same 
standardization parameters are listed in Table S2.
Figure 2 standardized cancer rates remain steady while a positive gain in annual percent change (aPC) leads to increasing crude rates.
Notes: Trends in cancer incidence (A) and mortality (B). Male and female hungarian crude rates of incidence and mortality are compared to age-standardized rates based 
on the 2013 European standard population (EsP 2013). solid lines represent actual data while dashed lines express data estimated by the age-period-cohort model. Every 
x-value represents a 5-year bin. Mean annual percent change in crude rates of male and female incidence (C) and mortality (D) modeled by joinpoint regression analysis. 
Positive aPC values represent increase, negative values decrease in mortality rates.
Abbreviation: n.s., not significant.
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Figure 3 Trends in incidence (A and B) and mortality (C and D) in the five most common cancers by sex.
Notes: solid lines represent crude rates, dashed lines represent rates age-adjusted to the 2013 EsP. For 2020, 2025, 2030 data are estimated by the age-period-cohort model.
Abbreviation: EsP, European standard population.
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Table 2 Mean annual percent change (aPC) and 95% Ci by sex in crude rate of incidence (a) and mortality (B) by site and time
(A)
APC, incidence in men (lower CI–upper CI) APC, incidence in women (lower CI–upper CI)
Site 2001–2014 2015–2030 Site 2001–2014 2015–2030
lung and bronchus 
−0.7* (−0.9 to −0.5) −0.7* (−0.9 to −0.5) Breast 1.5 (−0.6 to 3.7) 1.9* (1.6 to 2.2)
Colorectal 2.1* (1.9 to 2.3) 2.1* (1.9 to 2.3) Colorectal 1.3* (1.1 to 1.5) 1.3* (1.1 to 1.5)
Prostate 3.6* (3.1 to 4.1) 3.6* (3.1 to 4.1) lung and bronchus 1.7* (1.4 to 1.9) 1.7* (1.4 to 1.9)
Oral cavity and pharynx 
−0.7* (−1.0 to −0.4) −0.7* (−1.0 to −0.4) Corpus uteri 2.1* (1.7 to 2.4) 2.1* (1.7 to 2.4)
Bladder 2.5* (2.2 to 2.9) 2.5* (2.2 to 2.9) Cervix uteri 
−0.8 (−2.8 to 1.2) 0.5 (−0.9 to 1.9)
stomach 
−0.2 (−0.6 to 0.1) −0.2 (−0.6 to 0.1) Ovary 1.4 (−0.3 to 3.2) 0.8* (0.3 to 1.3)
Kidney 2.4* (2.0 to 2.7) 2.4* (2.0 to 2.7) stomach 0.1 (−0.2 to 0.4) 0.1 (−0.2 to 0.4)
Pancreas 2.6* (2.2 to 2.9) 2.6* (2.2 to 2.9) Pancreas 4.3* (3.2 to 5.4) 3.0* (2.5 to 3.4)
larynx 
−1.2* (−1.7 to −0.8) −1.2* (−1.7 to −0.8) Oral cavity and pharynx 2.7* (0.1 to 5.4) 1.5* (0.9 to 2.1)
Brain 0.8* (0.5 to 1.1) 0.8* (0.5 to 1.1) Brain 0.7* (0.3 to 1.2) 0.7* (0.3 to 1.2)
leukemia 2.3* (1.9 to 2.7) 2.3* (1.9 to 2.7) Melanoma of skin 4.6* (1.5 to 7.9) 2.6* (2.2 to 2.3)
Melanoma of skin 6.0* (4.2 to 7.9) 3.1* (2.3 to 3.9) Bladder 2.9* (2.5 to 3.3) 2.9* (2.5 to 3.3)
liver 4.1* (2.7 to 5.4) 1.9* (1.3 to 2.6) leukemia 1.6* (1.2 to 2.0) 1.6* (1.2 to 2.0)
non-hodgkin lymphoma 2.6* (2.2 to 3.0) 2.6* (2.2 to 3.0) Kidney 2.3* (2.0 to 2.6) 2.3* (2.0 to 2.6)
Esophagus 
−0.8* (−1.2 to −0.4) −0.8* (−1.2 to −0.4) gallbladder and biliary tract 0.7* (0.7 to 1.2) 0.7* (0.7 to 1.2)
Testis 2.0* (1.1 to 2.8) 0.3 (−0.3 to −0.9) non-hodgkin lymphoma 4.2* (3.3 to 5.0) 2.6* (1.3 to 3.8)
gallbladder and biliary tract 2.4* (1.9 to 3.0) 2.4* (1.9 to 3.0) liver 2.1* (1.6 to 2.6) 2.1* (1.6 to 2.6)
soft tissue 5.9* (3.3 to 8.6) 2.3* (1.2 to 3.5) soft tissue 5.6* (2.7 to 8.7) 1.7* (0.6 to 2.8)
Bones and joints 0.1 (−0.6 to 0.7) 0.1 (−0.6 to 0.7) Thyroid 4.2* (1.2 to 7.3) 2.5* (1.8 to 3.3)
Thyroid 3.2* (2.7 to 3.7) 3.2* (2.7 to 3.7) Bones and joints 0.1 (−0.5 to 0.7) 0.1 (−0.5 to 0.7)
(Continued)
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Table 3 ranking of incidence (a) and mortality (B) by expected percentages of the top 10 tumor types in males and females in 2020, 
2025, and 2030
(A) (B)
Incidence Mortality
Males  Females  Males  Females  
2020
 
 
 
 
 
Colorectal 16% Breast 19% 2020 lung and bronchus 29% lung and bronchus 22%
lung and bronchus 16% Colorectal 12% Colorectal 17% Colorectal 14%
Prostate 14% lung and bronchus 11% Prostate 8% Breast 14%
Bladder 7% Corpus uteri 4% Pancreas 6% Pancreas 7%
Oral cavity and pharynx 6% Pancreas 4% Oral cavity and pharynx 6% Ovary 5%
Kidney 4% Ovary 3% stomach 5% stomach 4%
Pancreas 4% Melanoma of skin 3% Bladder 4% leukemia 3%
Melanoma of skin 3% Bladder 3% liver 3% Cervix uteri 3%
stomach 3% Cervix uteri 3% leukemia 3% gallbladder and biliary tract 2%
leukemia 3% non-hodgkin lymphoma 3% Kidney 3% Kidney 2%
Other 24% Other 35% Other 17% Other 24%
2025
 
 
 
 
 
Colorectal 17% Breast 20% 2025 lung and bronchus 28% lung and bronchus 23%
Prostate 16% Colorectal 12% Colorectal 19% Colorectal 14%
lung and bronchus 14% lung and bronchus 11% Prostate 9% Breast 14%
Bladder 7% Pancreas 4% Pancreas 6% Pancreas 7%
Oral cavity and pharynx 6% Corpus uteri 4% stomach 5% Ovary 5%
Kidney 4% Melanoma of skin 3% Oral cavity and pharynx 5% stomach 4%
Pancreas 4% Ovary 3% Bladder 5% leukemia 3%
Melanoma of skin 4% Bladder 3% liver 3% Cervix uteri 3%
stomach 3% non-hodgkin lymphoma 3% leukemia 3% Kidney 2%
leukemia 3% Kidney 3% Kidney 3% gallbladder and biliary tract 2%
Other 23% Other 34% Other 15% Other 23%
2030
 
 
 
 
 
 
Colorectal 18% Breast 20% 2030 lung and bronchus 27% lung and bronchus 23%
Prostate 17% Colorectal 12% Colorectal 21% Colorectal 14%
lung and bronchus 13% lung and bronchus 11% Prostate 10% Breast 13%
Bladder 7% Pancreas 4% Pancreas 7% Pancreas 7%
Oral cavity and pharynx 5% Corpus uteri 4% Bladder 5% Ovary 5%
Kidney 4% Melanoma of skin 3% stomach 5% stomach 4%
Melanoma of skin 4% Ovary 3% Oral cavity and pharynx 4% leukemia 3%
Pancreas 4% Bladder 3% liver 4% Cervix uteri 3%
leukemia 3% non-hodgkin lymphoma 3% leukemia 3% Kidney 2%
stomach 3% soft tissue 3% Kidney 3% Bladder 2%
Other 22% Other 34% Other 12% Other 24%
Note: incidence and mortality are expressed as mean values for each year.
When comparing cancer incidence to the 2010–2012 
US data,16 the likelihood of developing LC and CRC was 
strikingly higher in both males and females, as was the 
probability of cancer risk over all sites, compared to the 
US (Table S3). The observed incidence rates of CRC, LC, 
oral cavity and pharynx cancer, bladder cancer, larynx 
cancer, melanoma, brain cancer, and testicular cancer were 
higher in Hungarian men compared to the 2012 estimated 
values of the worldwide male population, and the CRC, 
LC, pancreas cancer, melanoma, brain cancer, and kidney 
cancer incidence rates were greater among Hungarian 
women than the predicted rates of the worldwide female 
population. Similar trends persist when comparing cancer-
related mortality: the percentage of men who died from 
LC, CRC, oral cavity and pharynx cancer, pancreas cancer, 
and larynx cancer and the percentage of women who died 
from LC, CRC, and pancreas cancer were higher than the 
worldwide averages.
Discussion
Current scientific literature uses the yearly published prospec-
tive cancer incidence and mortality statistics of the USA as 
the gold standard for cancer epidemiology;16 the 2015 version 
of this report was already cited over 25,000 times. However, 
the age and demographic distribution of the US population 
is fundamentally different from other developed countries in 
Europe and Asia. These issues make the US data unreliable 
when projected to these countries.
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Figure 4 (Continued)
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Another concern of statistical analyses is the ESP, for which 
the first update since 1976 was in 2013. This means that rates 
standardized to the previous ESP are hardly comparable with 
recent data due to the rapid demographic shifts. Central and 
Eastern European countries share a similar history, have under-
gone comparable shifts in demography, and are facing similar 
challenges in their cancer epidemics. Within this region, with 
its 100% population coverage and relatively high autopsy rates, 
Hungarian statistics provide reliable data regarding trends in 
cancer epidemiology and the expected cancer rates for the 
near future, with the possibility of extrapolating projections 
for countries with similar trends in demography and cancer 
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Figure 4 Observed and projected tendencies of incidence and mortality in selected cancers in females (A) and males (B).
Note: solid lines are crude rates, dashed lines represent rates age-adjusted to the 2013 EsP (asr EsP 2013).
Abbreviations: asr, age-standardized rate; EsP, European standard Population.
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rates. However, our results cannot be generalized, although, 
in other countries of the European Union (e.g., France, Bel-
gium, and Denmark), the overall cancer incidence estimates 
for 2012 surpassed those of Hungary, the expected mortality 
was predicted in some cases to be as much as 30% lower.3 The 
discrepancy between per capita health expenditures between 
different countries may partially explain the disparity in 
expected mortality.17 The escalation of cancer incidence rates 
coupled with inadequate funding for health expenses in some 
countries could have grim consequences in the near future.
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Cancer risk varies geographically, leading to a substantial 
variation across native and immigrant populations.18 Immi-
gration rates differ between Western and Eastern parts of 
Europe considerably and are generally low in Hungary and in 
other Central and Eastern European countries as well. Stud-
ies on migration indicate that cancer rates among migrants 
and their descendants approach prevailing rates in the host 
country after they adopt the native lifestyle habits, includ-
ing smoking, diet, and reproductive behaviors.19 Taking into 
account the generally low migration rate in Hungary, we did 
not include migration in our model as an independent factor.
Currently, the lifetime probability of developing cancer in 
Hungary is 56.9% in men and 51.9% in women. The cancer 
burden of Hungary is still growing – by 2030 the population is 
projected to shrink by 6%, yet an approximately 35% increase 
in cancer incidence and 30% in cancer-related mortality are 
expected among those 65–85 years old. Improving treatment 
may also result in increased cancer prevalence, as cancer 
patients may live longer with their disease. The prospective 
increase in extended cancer care may impose additional 
challenges on the health care system.
While ASRs of male cancer incidence and mortality are 
declining, female ASRs for both incidence and mortality show 
a rising trend. Of note, incidence and mortality trends do not 
necessarily reflect each other, especially in certain cancers 
with typically high cure rates, such as melanoma and prostate 
cancer. In cancers with a worse prognosis, such as pancreatic 
cancer, incidence and mortality are more closely associated.
Between 2001 and 2015, four cancer sites, the lung, colon, 
breast, and prostate, accounted for most new cases diagnosed. 
In Europe, among the 11 most common cancers, almost two-
third are reported to be hypothetically preventable.20 When 
adjusting these tumor types to sex and incidence, a stunning 
77% of the cancer incidence in Hungarian men is made up 
of preventable malignancies.
Tobacco use is one of the major causes of preventable 
deaths.21 In addition to being responsible for approximately 
87–91% of lung cancers in men and 57–86% in women,22–24 
smoking has been linked to a dozen other cancers, including 
CRC and cancers of the pancreas, oral cavity and pharynx, 
bladder, and kidney. Although anti-smoking efforts achieved 
a fall in both smoking-related lung cancer incidence and 
mortality among men in the last two decades,25 smoking 
prevalence remains at 28% in Europe.26 Among Hungarian 
men, the extent of tobacco use started a steep decline in the 
1990s, leading to a constant decrease in tobacco-related 
malignancies. This development will still lead to appreciable 
reduction of cancers of the lung, oral cavity, larynx, and 
esophagus in the future (Figure 4B). However, the propor-
tion of daily smokers has been increasing among women in 
Central and Eastern Europe.27 Overall, lung cancer mortality 
in 2002–2012 in the Europe has increased by 17.5% among 
women.28 According to a 2014 survey, 29% of the Hungarian 
population smoked, 28% of those regularly, and the preva-
lence of smoking increased among those aged 18–34 years. 
Among men, 42% of young adults (18–34 years of age) and 
35% in middle age were smoking, while 29% and 27% of 
18–34-year-old and 35–65-year-old women were smokers, 
respectively (Central Statistical Office of Hungary).29 The 
soaring trends among young adults urge the resumption of 
anti-smoking campaigns aimed at vulnerable age groups.
The ASRs suggest an overall decline in both the incidence 
and mortality of stomach cancer among men and women. The 
pattern is comparable to steady decline of stomach cancer 
incidence and mortality of the past 40 years observed in Nor-
dic countries (Finland, Denmark, Iceland, Norway, and Swe-
den) – the cause of this decline is still not fully understood.30 
Nevertheless, crude rates provide the maximum information 
for local health legislation, and particularly among Hungarian 
men, crude rates of stomach cancer are predicted to remain 
on a moderately increasing trend.
The European incidence of CRC is highest in the former 
Czechoslovakia and Hungary.3,31 In Hungary, the incidence of 
CRC is increasing and is projected to surpass LC. Mortality 
rates are predicted to rise at an even more alarming pace, 
especially among women and older generations. Although 
CRC may be asymptomatic for a long time, a third of mortal-
ity could be preventable by adopting the annual fecal occult-
blood testing.32 Currently, of the 19 regions in Hungary, only 
four participate in an experimental model of biennial CRC 
screening, clearly insufficient to trigger a substantial change 
in the entire population. A chemo-preventive alternative 
would be the introduction of recommendations published 
by the US Preventive Services Task Force in 2015. In USA, 
regular use of aspirin has been described as a promising tool 
in CRC prevention when used in low daily doses for 10 years 
or longer in adults 50–59 years, and it may also be potentially 
effective among 60–69-year olds.33
Alcohol consumption has been directly linked to the 
development of colorectal, oral cavity and pharynx, esopha-
geal, liver, and female breast cancers,34 and up to 9% of 
cancer incidence is the result of excess alcohol consump-
tion in Europe.27 Excessive drinking habits can predestine a 
population to a high occurrence of alcohol-related cancers. 
People in Central and Eastern Europe, and particularly in 
Hungary, drink more alcohol per capita compared to the 
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rest of Europe, and among women, the highest proportion 
of alcohol consumption has been recorded in Hungary.35
High body mass index (BMI), defined by WHO as BMI 
>25 kg/m2, is associated with increased risk of cancer and 
continues to rise all across Europe.27 The prevalence of over-
weight and obesity is increasing in Hungary: according to a 
2014 study, 40.4% of adult males and 31.3% of females were 
overweight. Moreover, 32% of men and 31.5% of women 
were obese, and one-third of young men under 35 years of age 
already carried excess weight.36 Investigating 30 European 
countries, 2.5% of men and 4.1% of women cancer cases 
were attributable to excess BMI, mainly endometrial, breast, 
and colorectal cancers.37 Strong associations have also been 
found between high BMI and the risks of renal, esophageal 
adenocarcinoma, and thyroid cancers in men and esophageal 
adenocarcinoma, renal, and gallbladder cancers in women.38
Strikingly, upgrading the European reference population 
from the 1976 ESP to the most recent 2013 ESP increased 
ASRs dramatically, to up to 68%. Thus, many cancer cases 
were hidden due to the utilization of an outdated reference 
population. Moreover, the difference in almost all cancer 
types warns against the extrapolation of USA-based cancer 
epidemiology data to other countries, as the demographic 
difference renders USA data unreliable for Europe. Each 
country, or at least each continental region, should employ an 
updated reference population to better estimate the number 
of cases.
Limitation
A limitation of our study is the relative short follow-up 
compared, especially, to that from Nordic countries, where 
the follow-up started over 70 years ago (e.g., the Danish Can-
cer Registry was founded in 1942).39 However, despite this 
limitation, our study is the first to provide a comprehensive 
survey and prediction for the next 15 years by incorporating 
data obtained from different sources.
Conclusion
In summary, we present a state-of-the-art snapshot of cancer 
morbidity and mortality in Hungary. We corrected for biases 
that were present in previous analyses, including the inap-
propriate reference population and unsuitable standardiza-
tions. The updated demographic trends forecast a significant 
increase in crude rates of cancer incidence over the next 15 
years in Hungary. Our corrected estimates of cancer burden 
show the need for immediate and intensive prevention pro-
grams and targeted anticancer actions. Our projections may 
be suitably extrapolated to countries with similar predica-
ments in economics, demography, and cancer burden.
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